Combination of gemcitabine and cisplatin in treatment of advanced non-small-cell lung cancer

Objective: To evaluate the clinical efficacy and toxicity of combined gemcitabine and cisplatin in treatment of advanced non-small-cell lung cancer (NSCLC). Methods: Forty-two patients pathologically confirmed as stage Ⅲ or Ⅳ NSCLC were given Gemcitabine on d₁, and d₈ at a dose of 1 g/m² and cisplatin on d_1-3 at a dose of 30 mg/m². The chemotherapy was repeated every 21 days. Each patient was treated for at least 2 cycles. Results: Complete response was observed in 1case, partial response in 17 cases, no response in 16 cases and progression in 8 cases. The overall response rate was 42.9%. The main toxicities were gradeⅠ-Ⅱmyelosuppression, nausea and vomiting;however, there was no severe grade Ⅳ damage or obvious liver and kidney damage. Conclusions: Combination of gemcitabine and cisplatin is effective and well-tolerated in the treatment of advanced NSCLC.